Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
| ▸ | BCHE | P06276 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8097260 | 0.98 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL6014543 | 0.98 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL8092471 | 0.98 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL7756958 | 0.98 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL6014369 | 0.98 | SIGMAR1 (1.00) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL4065566 | 0.93 | SIGMAR1 (0.88) | SIGMAR1MAOACHRM2BCHEGAA | |
| Bromide SCHEMBL11691228 | 0.91 | SIGMAR1 (0.84) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL11883482 | 0.91 | SIGMAR1 (0.84) | SIGMAR1MAOACHRM2BCHEGAA | |
| SCHEMBL4932707 | 0.91 | MAOA (0.95) | SIGMAR1MAOACHRM2GAAMAPT | |
| SCHEMBL8851048 | 0.89 | MAOA (1.00) | SIGMAR1MAOACHRM2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1901902-A | Thiophene and benzothiophene hydroxamic acid derivatives | ATON PHARMA INC (US) | 2007-01-24 | — | — | CN | claimed |
| US-6057371-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-05-02 | — | — | US | claimed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | claimed |
| EP-0507863-A4 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | — | 1993-07-07 | — | — | EP | claimed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | claimed |
| EP-0507863-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1992-10-14 | — | — | EP | claimed |
| WO-1991009594-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1991-07-11 | — | — | WO | claimed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20230192591-A1 | PROCESS FOR PREPARING TRIENTINE DIHYDROCHLORIDE | COUGHLIN DANIEL J (US) | 2023-06-22 | — | — | US | disclosed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | disclosed |
| US-5162310-A | Calcium Metabolism Regulators | CIBA-GEIGY CORPORATION (US) | 1992-11-10 | — | — | US | disclosed |
| US-5157038-A | Antidepressants; tranquilizers; treatment of schizophrenia and epilepsy; antilepmic agents | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1992-10-20 | — | — | US | disclosed |
| EP-0412820-A2 | 2-Oxo-1-oxa-8-azaspiro[4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-02-13 | — | — | EP | disclosed |
| EP-0371921-A2 | Phenyl aliphatyl amino alkane diphosphonic acids | CIBA-GEIGY AG (CH) | 1990-06-06 | — | — | EP | disclosed |
| US-4416831-A | ANGIOTENSIN INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1983-11-22 | — | — | US | disclosed |
| US-4374131-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1983-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | SIGMAR1 2265/4885MAOA 1500/4885CHRM2 4783/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SIGMAR1 1818/4885MAOA 4632/4885CHRM2 1067/4885 |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SOD1, SOD3, SMN1; SMN2 | SIGMAR1 2242/4885MAOA 1513/4885CHRM2 4786/4885 |
| US-20230192591-A1 | PROCESS FOR PREPARING TRIENTINE DIHYDROCHLORIDE | SAMHD1, QDPR, DHPS | SIGMAR1 3092/4885MAOA 1882/4885CHRM2 4843/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | SIGMAR1 4873/4885MAOA 3656/4885CHRM2 3813/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SIGMAR1 4812/4885MAOA 4876/4885CHRM2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.